Brain Tumor Clinical Trials

Study: 2020-0478, A study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Physician name:  Dr. Rebecca Harrison
Phase I/II
Treatment agent: Selinexor, Temozolomide (TMZ), Lomustine (CCNU)
Disease: Glioblastoma Multiforme
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04421378

Study: 2017-0555, Tinostamustine With or Without Radiation Therapy in Treating Patient with Newly Diagnosed MGMT - Unmethlated Glioblastoma
Physician name:  Dr. Shiao-Pei Weathers
Phase I/II
Treatment agent: Tinostamustine
Disease: Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03452930

Study: 2019-1035, Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients with Newly Diagnosed MGMT Unmethlated Glioblastoma or Gliosarcoma
Physician name:  Dr. Nazanin Majd
Phase I
Treatment agent: Nedisertib, Temozolomide
Disease: Glioblastoma, Gliosarcoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04555577

Study: 2019-0216, A Trial  to Evaluate Multiple Regimens in Newly Diangosed and recurrent Glioblastoma (GBM AGILE)
Physician name: Dr. John de Groot
Phase II/III
Treatment agent: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Disease: Glioblastoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03970447

Study: 2019-1034, Study of Vorasidenib (AG-881) in Participants with Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Physician name: Dr. de Groot
Phase III
Treatment agent: Vorasidenib, Matching Placebo
Disease: Grade 2 Glioma, Residual Glioma, Recurrent Glioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04164901  

Study: 2015-0953, Oncolytic Adenovirus DNX-2401 in Treating Patients with Recurrent High-Grade Glioma
Physician name: Dr. Frederick Lang
Phase I
Treatment agent: Oncolytic Adenovirus Ad5-DNX-2401
Disease: IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03896568

Study: 2020-0478, A Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Physician name: Dr. Rebecca Harrison
Phase I/II
Treatment agent: Selinexor, Temozolomide (TMZ), Lomustine (CCNU)
Disease: Glioblastoma Multiforme
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04421378

Study: 2016-0859, A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype
Physician name: Dr. John de Groot
Treatment agent: Pembrolizumab
Disease: Glioma, Recurrent Malignant Glioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT02658279

Study: 2019-0216, A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)
Physician name: Dr. John de Groot
Phase II/III
Treatment agent: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Disease: Glioblastoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03970447

Study: 2018-045, A Phase II, Open-Label Study of ONC201 in Adults with Recurrent High-Grade Glioma
Physician name: Rebecca Harrison
Phase II
Treatment agent: ONC201
Disease: Glioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03295396  

Study: 2020-0124, Seizure control as a new metric in assessing efficacy of tumor treatment in patients with low grade glioma
Physician name: Rebecca Harrison
Treatment agent: Survey Administration
Disease: Brain Neoplasm, Low Grade Glioma, Seizure Disorder
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04553757

Study: #ALLIANCEA07160, Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma
Physician name: Dr. Carlos Kamiya Matsuoka
Phase II
Treatment agent: Vemurafenib, Cobimetinib
Disease: BRAF V600E Mutation Present, Papillary Craniopharyngioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03224767

Study: 2020-1111, Post-Surgical Stereotactic Radiosurgery (SRT) Versus GammaTile
Physician name: Dr. Jeffrey S. Weinberg
Phase III
Treatment agent: Oncolytic Adenovirus Ad5-DNX-2401
Disease: Brain Tumor: Recurrent, Primary, Metastatic, Glioblastoma, Meningioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04365374

Study: 2019-1064, Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Physician name: Dr. Barbara O'Brien
Phase II
Treatment agent: Abemaciclib, PI3K Inhibitor GDC-0084, Entrectinib
Disease: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03994796

Study: PA16-0496, Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN)
Physician name: Dr. Sujit Prabhu
Treatment agent: NeuroBlate System
Disease: Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT02392078

Study: 2012-0441, Prospective Study of White Blood Cells
Physician name: Dr. John de Groot
Treatment agent:  White blood cell and blood collection
Disease: Newly Diagnosed and Recurrent Glioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04838171

Study: 2015-0775,  Electrocorticography in Mapping Funcional Brain Areas During Surgery in Patients With Brian Tumors
Physician name: Dr. Sujit Prabhu
Treatment agent: N/A
Disease: Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Brain Neoplasm
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT02754544

Study: 2017-0663, Safety of MRI Compatible Hardware for MRI-based Image Guidance During Spine Surgery
Physician name: Dr. Claudio Tatsui
Phase I
Treatment agent: N/A
Disease: Thoracic Spine Neoplasm
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT04563806

Study: NCI10218, A Phase 1b Trial of CB-839 in Cobination with Radiation Therapy and Temozolomide in Patient with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma  Physician name: Dr. John de Groot
Phase I
Treatment agent: Telaglenastat Hydrochloride, Temozolomide
Disease: Anaplastic Astrocytoma, IDH-Mutant, Diffuse Astrocytoma, IDH-Mutant
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03528642

Study: 2020-0399, Early Supportive Care and Rehabilitation Intervention for Patients with High Grade Astrocytoma
Physician name: Dr. Rebecca Harrison

Study: 2016-0330, Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lmustine Alone in Patients with Anaplastic Asstrocytoma That progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
Physician name: Dr. Rebecca Harrison
Phase III
Treatment agent: Eflornithine, Lomustine
Disease: Anaplastic Astrocytoma, Recurrent Anaplastic Astrocytoma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT02796261

Study: 2020-0904, Immune Checkpoint Inhibitor Nivolumab in People with Recurrent Select Rare CNS Cancers
Physician name: Dr. Carlos Kamiya Matsuoka
Phase II
Treatment agent: Nivolumab
Disease: Medulloblastoma, Ependymoma, Pineal RegionTumors, Choroid Plexus Tumors, Atypical/Malignant Meningioma
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT03173950

Study: 2016-0684, A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas 
Physician name: Dr. Susan McGovern
Treatment agent: N/A
Disease: Meningioma, Brain Tumor
To learn more, visit ClinicalTrials.gov - NIH link: NCT No: NCT02693990

Study: PA18-0742, Metastatic Tumor Research and Outcomes Network (MTRON)
Physician name: Dr. Laurence Rhines
Disease: Metastatic Spine Tumor
To learn more, visit ClinicalTrials.gov - NIH link: No: NCT02830451